GLG News by Nephrologists (US)

This article addresses government policy, taxation, insurance, and socialization implications on future patient access to physician care.

Simply put, there's no incentive to be "emotionally supportive". In primary care, establishing a long term relationship between provider and patient evolves into a trusting relationship. Without the trust part, patient encounters are hollow, theatrical, and not supportive. There is no incentive to either...

Over the past 15 years there have been several long-term trials which have provided evidence that reduction of systolic pressure in an elderly population prevents the cognitive decline associated with ageing. The most recent studies have demonstrated the prevention of Alzheimer's-like symptoms. These...

Bisphosphonates, including medications like Fosamax, prevents normal bone turnover and metabolism.  Nephrologists had anticipated similar findings as these recent reports as over-suppression of normal bone turnover may be associated with adynamic bone disease and possibly fractures.  The process...

While no more would argue that control of systolic hypertension is crucial to preventing the consequences of hypertension such as congestive heart failure, MI's, left ventricular hyperthrophy, stroke and kidney failure there are other factors that are associated with these disease states. One of these...

I have used both Tekturna and Tekturna/HCTZ and I have found the combination to be more effective than Tekturna itself.  But I do not think it is worth the extra expense.  You can get great reductions in BP with lotrel which is generic but much cheaper. Tekturna does reduce proteinuria but...

You can give larger amounts of iv iron with Ferumoxytol compared to other IV forms  which in theory is nice but the advantage of the drug is in usage of the predialysis population

Tecturna or Aliskerin belongs to the new anti hypertensive medication class of direct renin inhibitor. The basic action is to inhibit the renin angiotensin/aldosterone system. As we all have understanding of how ace-i and ARB act in this system at different points and effect the blood pressure,...

This article brings more visibility to issue of effect of angiogenesis inhibitors on kidney function Other mechanisms of injury have previously been described.  Current case simply adds visibility and more definitive evidence of effect in humans Mechanism described is likely not restricted...

1- This analysis adds to the formalized analysis of the safety literature on ESA use in oncology. 2- Its timing will impact on the FDA CDER ODAC meeting scheduled to review Amgen and Ortho Biotech's ESA drugs.